<DOC>
	<DOCNO>NCT01428635</DOCNO>
	<brief_summary>The goal clinical research study learn eltrombopag help control prevent low platelet count patient receive treatment CML myelofibrosis .</brief_summary>
	<brief_title>Eltrombopag Management Thrombocytopenia Associated With Tyrosine Kinase Therapy Patients With Chronic Myeloid Leukemia ( CML ) Myelofibrosis ( MF )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , receive eltrombopag mouth 1 time day . Your dose may increase every 2 week depend platelet count response . You take eltrombopag empty stomach . You eat 2 hour take eltrombopag . You wait least 4 hour take eltrombopag take drug ( like antacid ) , dairy product , juice calcium add , supplement contain iron , calcium , aluminum , magnesium , selenium , zinc . Study Visits : Some routine blood draw list may do clinic near home . Ask study staff detail . The dose adjustment phase study doctor change dose study drug drug treatment CML myelofibrosis . During dose adjustment phase : - Before effective dose find , blood ( 1-2 tablespoon ) draw 1 time every week routine test check platelet count . - After effective dose find , blood ( 1-2 tablespoon ) draw 1 time month routine test check platelet count . During first year eltrombopag therapy , every 3-4 month : - Your medical history record . - You physical exam , include measurement height , weight , vital sign . - You ask side effect may drug may take . - You standard-of-care bone marrow aspiration and/or biopsy check status disease . This sample also use genetic research test . If aspirate collect , blood ( 1 teaspoon ) drawn test . After first year eltrombopag therapy , every 6 month , return clinic test procedure perform list . You bone marrow aspiration and/or biopsy every 12 month first year check status disease . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete end-of-treatment visit . End-of-Treatment Visit : About 30 day last dose study drug , return clinic end-of-treatment visit . - You physical exam , include measurement height , weight , vital sign . - You ask side effect may . - Blood ( 1-2 tablespoon ) draw routine test . This blood also use check platelet count . This investigational study . Eltrombopag FDA approve commercially available treatment patient low platelet count . The use eltrombopag treatment low platelet count patient CML myelofibrosis investigational . Up 39 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>1 . CML patient chronic phase receive treatment FDA approve TKI ; CML patient accelerate blastic phase consider phase thrombocytopenia clonal evolution criterion accelerated/blastic phase patient myelofibrosis receive treatment FDA approve TKI peripheral blood and/or bone marrow blast &lt; /= 10 % . 2 . Grade &gt; /= 3 thrombocytopenia ( platelet &lt; 50 x 10^9/L ) first 3 month therapy TKI patient CML platelet &lt; 100 x 10^9/L patient MF first 3 month therapy . Thrombocytopenia must either recurrent ( i.e. , second great episode thrombocytopenia ) require dose reduction TKI . 3 . Subject anticipated therapy TKI continue &gt; /= 3 month 4 . Adequate organ function : Total bilirubin ( except Gilbert 's Syndrome ) &lt; /= 1.5 x ULN ; ALT AST &lt; 3 x ULN ; Creatinine &lt; /= 2 x ULN 1 . CML patient accelerate blastic phase except consider phase thrombocytopenia clonal evolution criterion accelerated/blastic phase ; myelofibrosis patient transform acute leukemia &gt; /= 10 % blast peripheral blood and/or bone marrow . 2 . Thrombocytopenia consider unrelated treatment TKI accelerate phase define ; 3 . Age &lt; 18 year ; 4 . Stem cell transplantation within precede 60 day prior registration ; 5 . Patients document active hepatitis B C infection ; 6 . Patients know bone marrow reticulin fibrosis ( &gt; /= grade 2 ) ( applicable patient CML ) ; 7 . Patients palpable splenomegaly &gt; /= 16cm coastal margin ( applicable patient CML ) . 8 . Female subject pregnant breastfeeding . Women childbearing potential require BHCG serum urine pregnancy test perform within 7 day prior first study drug dose . A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential men must agree use contraception prior study entry duration study participation . 9 . Patients know risk factor thromboembolism ( e.g . Factor V Leiden mutation , ATIII deficiency , Protein C S deficiency , antiphospholipid syndrome , portal hypertension , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Tyrosine kinase therapy</keyword>
	<keyword>TKI</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Platelet count</keyword>
	<keyword>Clonal evolution</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>Promacta</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>MF</keyword>
</DOC>